Postpartum hemorrhage

E-mail Print PDF

Postpartum haemorrhage (PPH) is a major cause of mortality, morbidity and long term disability related to pregnancy and
childbirth. According to Global Health Observatory (WHO), almost 200 women die daily world-wide in childbirth due to PPH.
Giving birth to a child is one of the miracles of life, but every eight minutes, this joy can turn to be a tragedy, where a loss of
a mother shatters a family and threatens the well-being of surviving children. Evidence shows that infants whose mothers die
are more likely to die before reaching their second birthday than infants whose mothers survive. And for every woman who
dies, 20 or more experience serious complications because of PPH. As an example, in Malawi alone, the maternal mortality
due to PPH is 1.1 deaths per 100 births.

Of the hundreds of thousands of women who die during childbirth, 90% live in Africa and Asia. It should be the goal for every
pregnancy, that the birth is safe. Predicting who will have PPH based on risk factors is difficult because two-thirds of women
who have PPH have no risk factors. Therefore, all women are considered at risk, and PPH prevention must be incorporated
into care provided at every birth.

Rapid absorption and short time of onset is of major importance when a life threatening situation occurs and a in this case,
there is a need for appropriate therapeutics. IV administration provides the most rapid absorption and onset time. However,
many drugs are not available in such formulations or require freezer or refrigeration due to poor stability. Work, carried out
at Hananja has shown that intranasal administration may provide similar pharmacokinetics as intramuscular injections with
time of onset around ½ -1½ min. Hananja’s goal is to develop a nasally administered rescue medicine to treat women having
PPH. The very important drug, misoprostol, is only available as oral tablets and used “off label” and placed into the rectum.
Such an important drug should be available in a more applicable form in such a way that it may be delivered immediately, not
as 5-6 tablets to be forced into the rectum.

The aim is to receive orphan drug status and fast-track, so this project may be brought through necessary non-clinical and
preclinical phases into the clinical phase I trials within the next 2-3 years, having a product ready to enter the market in about
5½ years or early/mid 2018.

The pharmaceutical industry has been contacted, but there is no interest because the product is needed in the developing
countries and will not provide enough revenues for the shareholders.

Furthermore, another goal of this project is to establish a network of people, international organizations and societies,
interested in fighting maternal death caused by PPH to assist funding this development program.

Þú ert hér: Home Our Projects Postpartum hemorrhage

Support center

Hananja plc

  • Address: Aflagrandi 7
  • City: 107 Reykjavík, Iceland
  • Tel: (+354) 898-0318
  • Email: sg@hananja.com